AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25837215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro:K
Number of subjects: 547
Study 23256605 — intervention group
Group type: EXPERIMENTAL
Intervention: Freestyle Navigator (FSN)
Number of subjects: 52
Study 23256605 — intervention group
Group type: COMPARATOR
Intervention: Dexcom SEVEN PLUS (DSP)
Number of subjects: 52
Study 21622587 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg q.d.
Number of subjects: 1598
Study 21622587 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg q.d.
Number of subjects: 1598
Study 18655566 — intervention group
Group type: EXPERIMENTAL
Intervention: E-leng Capsule (ELC) administered before and after operation for 3 months starting from the 7th day post-operation
Number of subjects: 60
Study 18655566 — intervention group
Group type: COMPARATOR
Intervention: Danazol administered from the 7th day post-operation for 3 months (Control group)
Number of subjects: 60
Study 18655566 — intervention group
Group type: EXPERIMENTAL
Intervention: E-leng Capsule (ELC)
Number of subjects: 60
Study 18655566 — intervention group
Group type: COMPARATOR
Intervention: Danazol (Control group)
Number of subjects: 60
Study 16959188 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine 4 mL with 20 microg epinephrine
Number of subjects: 90
Study 16959188 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine 4 mL with 40 microg epinephrine
Number of subjects: 90
Study 16959188 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine 4 mL with 0 microg epinephrine
Number of subjects: 90
Study 12792424 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock report with comprehensive content
Number of subjects: 0
Study 12792424 — intervention group
Group type: COMPARATOR
Intervention: Mock report with less comprehensive content
Number of subjects: 0
Study 10690160 — intervention group
Group type: COMPARATOR
Intervention: saccharin (control, 23 kJ)
Number of subjects: 80
Study 10690160 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g sucrose (859 kJ)
Number of subjects: 80
Study 10690160 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g maize oil (1569 kJ)
Number of subjects: 80
Study 10690160 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g sucrose, 20 g maize oil (1213 kJ)
Number of subjects: 80
Study 8623811 — intervention group
Group type: EXPERIMENTAL
Intervention: P6 acupressure
Number of subjects: 161
Study 8623811 — intervention group
Group type: COMPARATOR
Intervention: Placebo (acupressure bands inappropriately placed)
Number of subjects: 161
Study 8623811 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 161
Study 1773870 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 in solid gel (Cerviprost)
Number of subjects: 80
Study 1773870 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg PGE2 in liquid cellulose-gel
Number of subjects: 80
Study 6115001 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN
Number of subjects: 21
Study 6115001 — intervention group
Group type: COMPARATOR
Intervention: Control (glucose-electrolyte)
Number of subjects: 21
Study 31090511 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg SHIP1 activator
Number of subjects: 298
Study 31090511 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg SHIP1 activator
Number of subjects: 298
Study 31090511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 28183441 — intervention group
Group type: EXPERIMENTAL
Intervention: SITLegs (repeated sprints on a cycle ergometer)
Number of subjects: 12
Study 28183441 — intervention group
Group type: EXPERIMENTAL
Intervention: SITArms (repeated sprints on an arm-crank ergometer)
Number of subjects: 12
Study 28183441 — intervention group
Group type: COMPARATOR
Intervention: END (50-min continuous cycling at 65% V̇O2max)
Number of subjects: 12
Study 25125635 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 73
Study 25125635 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 22661410 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS over the left pre-SMA (5 pulses, 10 Hz)
Number of subjects: 18
Study 22661410 — intervention group
Group type: COMPARATOR
Intervention: Vertex stimulation (control condition)
Number of subjects: 18
Study 21206277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon lidocaine injection (2% lidocaine)
Number of subjects: 260
Study 21206277 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection (1 ml)
Number of subjects: 260
Study 21206277 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 260
Study 21206277 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anaesthesia
Number of subjects: 260
Study 18502614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemic patients
Number of subjects: 87
Study 18502614 — intervention group
Group type: COMPARATOR
Intervention: Epileptic patients with normal t-Hcy levels
Number of subjects: 87
Study 18502614 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects with normal t-Hcy levels
Number of subjects: 87
Study 16610158 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV seropositives (HIV +)
Number of subjects: 246
Study 12970893 — intervention group
Group type: EXPERIMENTAL
Intervention: UCBT
Number of subjects: 153
Study 12970893 — intervention group
Group type: EXPERIMENTAL
Intervention: UCBT+PE
Number of subjects: 153
Study 12970893 — intervention group
Group type: COMPARATOR
Intervention: Adult plasma (control)
Number of subjects: 153
Study 12970893 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 153
Study 12970893 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonate cord blood
Number of subjects: 153
Study 12970893 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 153
Study 11788013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide therapy
Number of subjects: 22
Study 9459393 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg p24-VLP in Alum adjuvant
Number of subjects: 15
Study 9459393 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg p24-VLP in Alum adjuvant
Number of subjects: 15
Study 9459393 — intervention group
Group type: COMPARATOR
Intervention: Aluminium hydroxide placebo
Number of subjects: 15
Study 9459393 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 15
Study 16353581 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI) 12.5 mg
Number of subjects: 19
Study 3356082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (325 mg) with methyldopa (500 mg)
Number of subjects: 12
Study 3356082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous gluconate (600 mg) with methyldopa (500 mg)
Number of subjects: 12
Study 3356082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (325 mg) in hypertensive subjects
Number of subjects: 12
Study 29534131 — intervention group
Group type: EXPERIMENTAL
Intervention: Trephine core procedure
Number of subjects: 0
Study 29534131 — intervention group
Group type: COMPARATOR
Intervention: Bone-added osteotome sinus floor elevation technique
Number of subjects: 0
Study 27752170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/(kg×h))
Number of subjects: 60
Study 27752170 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 60
Study 24117597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide one-step dose increase
Number of subjects: 484
Study 24117597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide two-step dose increase
Number of subjects: 484
Study 24117597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study 23355162 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (n = 50)
Number of subjects: 100
Study 23355162 — intervention group
Group type: COMPARATOR
Intervention: Tacks (n = 50)
Number of subjects: 100
Study 20308907 — intervention group
Group type: COMPARATOR
Intervention: Propofol 200 mg
Number of subjects: 20
Study 20308907 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 350 mg
Number of subjects: 20
Study 18093197 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen sponge (GC)
Number of subjects: 200
Study 18093197 — intervention group
Group type: COMPARATOR
Intervention: Primary closure (PC)
Number of subjects: 200
Study 16649860 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups of 3, 4, and 5 people
Number of subjects: 0
Study 16649860 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-person groups
Number of subjects: 0
Study 12166353 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine
Number of subjects: 59
Study 12166353 — intervention group
Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 59
Study 9864711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (1 mg daily for 3-12 months)
Number of subjects: 44
Study 9864711 — intervention group
Group type: COMPARATOR
Intervention: Selegiline and Vitamin E (control group)
Number of subjects: 44
Study 7621648 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline contrast transoesophageal echocardiography with the Valsalva manoeuvre
Number of subjects: 28
Study 7621648 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal colour Doppler echocardiography
Number of subjects: 28
Study 7621648 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic colour Doppler echocardiography
Number of subjects: 28
Study 7621648 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 2912000 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (Zn) supplementation
Number of subjects: 0
Study 2912000 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (Zn) and Iron (Fe) supplementation
Number of subjects: 0
Study 330168 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprindine
Number of subjects: 98
Study 330168 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 98
Study 330168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 6958187 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural change treatment programme (Section II)
Number of subjects: 0
Study 6958187 — intervention group
Group type: COMPARATOR
Intervention: Cardiologist-led treatment programme (Section I)
Number of subjects: 0
Study 6958187 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular care from own physician)
Number of subjects: 0
Study 6958187 — intervention group
Group type: COMPARATOR
Intervention: Dropout comparison group
Number of subjects: 0
Study 31128057 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE (ifosfamide, carboplatin, and etoposide)
Number of subjects: 61
Study 31128057 — intervention group
Group type: COMPARATOR
Intervention: TC (topotecan/cyclophosphamide)
Number of subjects: 61
Study 30099285 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness course (n=107)
Number of subjects: 185
Study 30099285 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n=78)
Number of subjects: 185
Study 26329838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport rock climbing (SRC) exercises for 60 minutes a day, three days a week for 8 weeks
Number of subjects: 19
Study 24771196 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic transaxillary cervical (TAC) parathyroidectomy
Number of subjects: 14
Study 24771196 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic transthoracic mediastinal (TTM) parathyroidectomy
Number of subjects: 14
Study 21739158 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 2/3 of I.V. predicted carboplatin dose by I.V. infusion and the rest 1/3 as aerosol (jet nebulised D1)
Number of subjects: 60
Study 21739158 — intervention group
Group type: COMPARATOR
Intervention: Group A: I.V. chemotherapy (carboplatin AUC ≈ 5.5 D1)
Number of subjects: 60
Study 19298231 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus F19
Number of subjects: 179
Study 19298231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 17897478 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol plus fluticasone propionate (SFC)
Number of subjects: 66
Study 17897478 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate plus montelukast (FP/M)
Number of subjects: 66
Study 15240584 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.074 mg/kg, sc three times per week)
Number of subjects: 68
Study 15240584 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 68
Study 12191749 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 7.5 cmH(2)O pressure
Number of subjects: 58
Study 12191749 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy (60% inhaled oxygen)
Number of subjects: 58
Study 9707845 — intervention group
Group type: EXPERIMENTAL
Intervention: KOH preparation
Number of subjects: 144
Study 9707845 — intervention group
Group type: COMPARATOR
Intervention: Gram's stain
Number of subjects: 144
Study 9707845 — intervention group
Group type: COMPARATOR
Intervention: LPCB
Number of subjects: 144
Study 9707845 — intervention group
Group type: EXPERIMENTAL
Intervention: CFW
Number of subjects: 144
Study 9707845 — intervention group
Group type: EXPERIMENTAL
Intervention: KOH preparation and CFW
Number of subjects: 144
Study 7621489 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.24% NaF/silica abrasive dentifrice containing 0.3% triclosan/2.0% copolymer
Number of subjects: 3462
Study 7621489 — intervention group
Group type: COMPARATOR
Intervention: Similar dentifrice without triclosan/copolymer
Number of subjects: 3462
Study 2239797 — intervention group
Group type: EXPERIMENTAL
Intervention: 465 kcal/d (HE group)
Number of subjects: 542
Study 2239797 — intervention group
Group type: COMPARATOR
Intervention: 52 kcal/d (LE group)
Number of subjects: 542
Study 407963 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition with a high calorie and nitrogen content (group A)
Number of subjects: 15
Study 407963 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dextrose/saline solution (group B)
Number of subjects: 15
Study 31493054 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct defect closure
Number of subjects: 241
Study 31493054 — intervention group
Group type: COMPARATOR
Intervention: No direct defect closure
Number of subjects: 241
Study 31271193 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine intake ranging from 7.20 to 40.0 mg .kg‐1 .d‐1
Number of subjects: 12
Study 31271193 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation to a milkshake diet providing protein at 1.0 g.kg‐1 .d‐1 and energy at 1.7 × REE for two days prior to study
Number of subjects: 12
Study 31271193 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct amino acid oxidation method measuring oxidation of l‐[1‐13C]phenylalanine to 13CO2
Number of subjects: 12
Study 28154796 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous feedback (n=7)
Number of subjects: 14
Study 28154796 — intervention group
Group type: COMPARATOR
Intervention: Intermittent feedback (n=7)
Number of subjects: 14
Study 25993119 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab (anti-IFNAR1 receptor antibody)
Number of subjects: 0
Study 24925440 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg every 12 h on day 1, then 300 mg every 12 h for 27.5 days)
Number of subjects: 36
Study 24925440 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 36
Study 24925440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21775147 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage ACL revision technique using calcium phosphate bone cement
Number of subjects: 10
Study 21775147 — intervention group
Group type: COMPARATOR
Intervention: Standard reconstruction with bone-patellar tendon-bone autograft with bioabsorbable interference screw fixation (Control)
Number of subjects: 10
Study 19317630 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 4301
Study 19317630 — intervention group
Group type: COMPARATOR
Intervention: Other antidepressants (citalopram, duloxetine, fluoxetine, paroxetine, sertraline, venlafaxine)
Number of subjects: 4301
Study 17584698 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol for 10 to 12 months
Number of subjects: 46
Study 17584698 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals (control group)
Number of subjects: 46
Study 15201999 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 263
Study 12365828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis with recombinant pro-urokinase (r-pro-UK)
Number of subjects: 0
Study 12365828 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial thrombolysis with other agents
Number of subjects: 0
Study 10214787 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy (PT) under bronchoscopic surveillance
Number of subjects: 130
Study 10214787 — intervention group
Group type: COMPARATOR
Intervention: Open tracheostomy (OT)
Number of subjects: 130
Study 10214787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost estimation for PT
Number of subjects: 130
Study 8545790 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Split course radiotherapy (1.8 to 2 Gy single dose) over 10 weeks with chemotherapy (5‐FU, methotrexate, cyclophosphamide)
Number of subjects: 48
Study 8545790 — intervention group
Group type: COMPARATOR
Intervention: Group B: Conventional radiotherapy (1.8 to 2 Gy single dose) over 6 weeks with chemotherapy (5‐FU, mitomycin C)
Number of subjects: 48
Study 2227074 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release theophylline
Number of subjects: 104
Study 2227074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 345993 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 47
Study 345993 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 47
Study 345993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30878323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (4 tailored educational sessions by a community health worker + text messaging until birth)
Number of subjects: 230
Study 30878323 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (daily capsules containing Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12)
Number of subjects: 230
Study 30878323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 230
Study 30878323 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 230
Study 27634419 — intervention group
Group type: EXPERIMENTAL
Intervention: NGF injection in infrapatellar fat pad (IFP) followed by acid infusion (5 mL of phosphate-buffered acidic saline at 20 mL/h)
Number of subjects: 32
Study 27634419 — intervention group
Group type: EXPERIMENTAL
Intervention: NGF injection in tibialis anterior (TA) muscle followed by acid infusion (10 mL at 30 mL/h)
Number of subjects: 32
Study 27634419 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection in infrapatellar fat pad (IFP) followed by acid infusion (5 mL of phosphate-buffered acidic saline at 20 mL/h)
Number of subjects: 32
Study 27634419 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection in tibialis anterior (TA) muscle followed by acid infusion (10 mL at 30 mL/h)
Number of subjects: 32
Study 25843816 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone 8 mg
Number of subjects: 40
Study 25843816 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 40
Study 25843816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 24716610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous KGF (60 μg/kg) for 3 days
Number of subjects: 0
Study 24716610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24716610 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro BAL fluid from KGF-treated subjects
Number of subjects: 0
Study 24716610 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL from KGF-pretreated group
Number of subjects: 0
Study 24716610 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of GM-CSF receptor activation
Number of subjects: 0
Study 22879574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management algorithms coupled with a comprehensive adoption program
Number of subjects: 485
Study 22879574 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 485
Study 19390327 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV/r (boosted atazanavir)
Number of subjects: 248
Study 19390327 — intervention group
Group type: COMPARATOR
Intervention: LPV/r (boosted lopinavir)
Number of subjects: 248
Study 17703258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral insufficiency
Number of subjects: 0
Study 17703258 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate mitral insufficiency
Number of subjects: 0
Study 15450725 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment time of radiotherapy reduced to 5.5 weeks, 6.5 weeks, and 9.5 weeks with a total dose of 66-68 Gy, 2 Gy/fx.
Number of subjects: 209
Study 11520380 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System (CHESS)
Number of subjects: 246
Study 9746769 — intervention group
Group type: EXPERIMENTAL
Intervention: D-FISH technique for monitoring therapy in CML
Number of subjects: 10
Study 9746769 — intervention group
Group type: EXPERIMENTAL
Intervention: D-FISH analysis of interphase nuclei from blood
Number of subjects: 10
Study 9746769 — intervention group
Group type: EXPERIMENTAL
Intervention: D-FISH analysis
Number of subjects: 10
Study 9746769 — intervention group
Group type: EXPERIMENTAL
Intervention: D-FISH technique
Number of subjects: 10
Study 7911136 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-micrograms bolus injection of somatostatin + 250 micrograms/h slow infusion
Number of subjects: 19
Study 7911136 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-micrograms bolus injection of somatostatin + 250 micrograms/h slow infusion
Number of subjects: 19
Study 7911136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19